Among 94 older adults with HIV who completed a 16-week randomized exercise trial, pre-frailty and frailty prevalence dropped sharply from 48.9% to 30.9%—a 37% relative reduction. Improvements were driven primarily by gains in exhaustion and low physical activity rather than changes in sarcopenia, which was surprisingly rare at baseline. Both high-intensity interval training (HIIT) and continuous moderate exercise (CME) combined with progressive resistance training produced comparable results. Critically, pre-frail participants who stayed in the trial improved 400-meter walk speed by 7.1% versus 4.6% in non-frail peers, and reported meaningful fatigue reduction of 3.3 points—neither effect seen in non-frail completers.
This finding carries real clinical weight. HIV-positive adults on modern antiretroviral therapy age atypically fast, accumulating frailty a decade earlier than HIV-negative peers through chronic inflammation, mitochondrial dysfunction, and metabolic disruption. Intervention data for this population have been scarce, making the HEALTH Trial a meaningful addition. The dose-response pattern—greater baseline vulnerability producing greater functional gain—mirrors what's seen in general geriatric exercise literature and argues for prioritizing the most impaired patients rather than the healthiest.
The study's central limitation is a 20% dropout rate, and frail participants withdrew disproportionately (p=0.03), introducing survivorship bias that likely flatters the results. With only 118 enrollees and mostly male participants (85%), generalizability is constrained. Still, the finding that moderate and high-intensity exercise perform equivalently is pragmatically useful—lower-intensity protocols may improve retention in this vulnerable group.
